June 25, 2025

CheckMate9-ER Trial: Outcomes Across Risk Subgroups and Sites of Metastases

Dr. Pedro Barata discusses the positive impact of cabozantinib+nivolumab treatment for high-risk patients with advanced renal cell carcinoma, including subgroups of patients with liver, lung, or bone metastases.

More Expert Perspectives in RCC:

CheckMate-9ER Trial: How Cabozantinib+Nivolumab Preserves Quality of Life in Advanced RCC

Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.

CheckMate-9ER Trial: Safety and Tolerability Outcomes

Dr. Vincent Xu discusses the safety and tolerability outcomes from the CheckMate-9ER trial, which evaluated the use of cabozantinib+nivolumab in the treatment of advanced renal cell carcinoma.

CheckMate-9ER Trial Update: Five-year Follow-up Data on Advanced Renal Cell Carcinoma

Dr. Yasser Ged discusses five-year follow-up data from the CheckMate-9ER trial, which studied the use of cabozantinib+nivolumab in patients with previously untreated advanced renal cell carcinoma.

Efficacy of First- and Second-line Cabozantinib Treatment in Advanced RCC

Dr. Michael Devitt discusses the efficacy of cabozantinib as a first- and second-line treatment option for patients with advanced renal cell carcinoma (RCC).